Genetically engineered tetravalent single-chain Fv of the pancarcinoma monoclonal antibody CC49

Improved biodistribution and potential for therapeutic application

A. Goel, D. Colcher, J. Baranowska-Kortylewiez, Samuel C. Augustine, B. J M Booth, G. Pavlinkova, S. K. Batra

Research output: Contribution to journalArticle

101 Citations (Scopus)

Abstract

Failure of radiolabeled monoclonal antibodies (MAbs) in the treatment of solid tumors, for the most part, is a result of undesirable pharmacokinetics that lead to significant radiation exposure of normal tissues and an inadequate delivery of radiation doses to tumors. Using genetic engineering, antitumor MAbs can be optimized for desirable clinical applications. In the present study, we report the generation of a tetravalent single-chain Fv {[sc(Fv)2]2} of the murine MAb CC49 that recognizes the tumor-associated glycoprotein, TAG-72. [Sc(Fv)2]2 was expressed as a secreted soluble protein in Pichia pastoris under the regulation of alcohol oxidase 1 promoter. The in vitro binding properties of the tetravalent construct were analyzed by solid-phase RIA and surface plasmon resonance studies using BIAcore. The binding affinity constant (KA) for the [sc(Fv)2]2 and CC49 IgG were similar, i.e., 1.02 × 108 M-l and 1.14 × l08 M-1, respectively, and were 4-fold higher than its divalent scFv [sc(Fv)2; 2.75 × 107 M-1. At 6 h postadministration, the percentage of injected dose accumulated/g of LS-174T colon carcinoma xenografts was 21.3 ± 1.3, 9.8 ± 1.3, and 17.3 ± 1.1 for radioiodinated [sc(Fv)2]2, sc(Fv)2, and IgG, respectively. Pharmacokinetic analysis of blood clearance studies showed the elimination half-life for [sc(Fv)2]2, sc(Fv)2, and IgG as 170, 80, and 330 min, respectively. The gain in avidity resulting from multivalency along with an improved biological half-life makes the tetravalent construct an important reagent for cancer therapy and diagnosis in MAb-based radiopharmaceuticals.

Original languageEnglish
Pages (from-to)6964-6971
Number of pages8
JournalCancer Research
Volume60
Issue number24
StatePublished - Dec 15 2000
Externally publishedYes

Fingerprint

Single-Chain Antibodies
Immunoglobulin G
Monoclonal Antibodies
alcohol oxidase
Half-Life
Pharmacokinetics
Neoplasms
Genetic Engineering
Pichia
Surface Plasmon Resonance
Radiopharmaceuticals
Heterografts
Colon
Therapeutics
Radiation
Carcinoma
Proteins
tumor-associated antigen 72

All Science Journal Classification (ASJC) codes

  • Cancer Research
  • Oncology

Cite this

Genetically engineered tetravalent single-chain Fv of the pancarcinoma monoclonal antibody CC49 : Improved biodistribution and potential for therapeutic application. / Goel, A.; Colcher, D.; Baranowska-Kortylewiez, J.; Augustine, Samuel C.; Booth, B. J M; Pavlinkova, G.; Batra, S. K.

In: Cancer Research, Vol. 60, No. 24, 15.12.2000, p. 6964-6971.

Research output: Contribution to journalArticle

Goel, A, Colcher, D, Baranowska-Kortylewiez, J, Augustine, SC, Booth, BJM, Pavlinkova, G & Batra, SK 2000, 'Genetically engineered tetravalent single-chain Fv of the pancarcinoma monoclonal antibody CC49: Improved biodistribution and potential for therapeutic application', Cancer Research, vol. 60, no. 24, pp. 6964-6971.
Goel, A. ; Colcher, D. ; Baranowska-Kortylewiez, J. ; Augustine, Samuel C. ; Booth, B. J M ; Pavlinkova, G. ; Batra, S. K. / Genetically engineered tetravalent single-chain Fv of the pancarcinoma monoclonal antibody CC49 : Improved biodistribution and potential for therapeutic application. In: Cancer Research. 2000 ; Vol. 60, No. 24. pp. 6964-6971.
@article{8622d2769b1b48b7a4c39fee76d000db,
title = "Genetically engineered tetravalent single-chain Fv of the pancarcinoma monoclonal antibody CC49: Improved biodistribution and potential for therapeutic application",
abstract = "Failure of radiolabeled monoclonal antibodies (MAbs) in the treatment of solid tumors, for the most part, is a result of undesirable pharmacokinetics that lead to significant radiation exposure of normal tissues and an inadequate delivery of radiation doses to tumors. Using genetic engineering, antitumor MAbs can be optimized for desirable clinical applications. In the present study, we report the generation of a tetravalent single-chain Fv {[sc(Fv)2]2} of the murine MAb CC49 that recognizes the tumor-associated glycoprotein, TAG-72. [Sc(Fv)2]2 was expressed as a secreted soluble protein in Pichia pastoris under the regulation of alcohol oxidase 1 promoter. The in vitro binding properties of the tetravalent construct were analyzed by solid-phase RIA and surface plasmon resonance studies using BIAcore. The binding affinity constant (KA) for the [sc(Fv)2]2 and CC49 IgG were similar, i.e., 1.02 × 108 M-l and 1.14 × l08 M-1, respectively, and were 4-fold higher than its divalent scFv [sc(Fv)2; 2.75 × 107 M-1. At 6 h postadministration, the percentage of injected dose accumulated/g of LS-174T colon carcinoma xenografts was 21.3 ± 1.3, 9.8 ± 1.3, and 17.3 ± 1.1 for radioiodinated [sc(Fv)2]2, sc(Fv)2, and IgG, respectively. Pharmacokinetic analysis of blood clearance studies showed the elimination half-life for [sc(Fv)2]2, sc(Fv)2, and IgG as 170, 80, and 330 min, respectively. The gain in avidity resulting from multivalency along with an improved biological half-life makes the tetravalent construct an important reagent for cancer therapy and diagnosis in MAb-based radiopharmaceuticals.",
author = "A. Goel and D. Colcher and J. Baranowska-Kortylewiez and Augustine, {Samuel C.} and Booth, {B. J M} and G. Pavlinkova and Batra, {S. K.}",
year = "2000",
month = "12",
day = "15",
language = "English",
volume = "60",
pages = "6964--6971",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "24",

}

TY - JOUR

T1 - Genetically engineered tetravalent single-chain Fv of the pancarcinoma monoclonal antibody CC49

T2 - Improved biodistribution and potential for therapeutic application

AU - Goel, A.

AU - Colcher, D.

AU - Baranowska-Kortylewiez, J.

AU - Augustine, Samuel C.

AU - Booth, B. J M

AU - Pavlinkova, G.

AU - Batra, S. K.

PY - 2000/12/15

Y1 - 2000/12/15

N2 - Failure of radiolabeled monoclonal antibodies (MAbs) in the treatment of solid tumors, for the most part, is a result of undesirable pharmacokinetics that lead to significant radiation exposure of normal tissues and an inadequate delivery of radiation doses to tumors. Using genetic engineering, antitumor MAbs can be optimized for desirable clinical applications. In the present study, we report the generation of a tetravalent single-chain Fv {[sc(Fv)2]2} of the murine MAb CC49 that recognizes the tumor-associated glycoprotein, TAG-72. [Sc(Fv)2]2 was expressed as a secreted soluble protein in Pichia pastoris under the regulation of alcohol oxidase 1 promoter. The in vitro binding properties of the tetravalent construct were analyzed by solid-phase RIA and surface plasmon resonance studies using BIAcore. The binding affinity constant (KA) for the [sc(Fv)2]2 and CC49 IgG were similar, i.e., 1.02 × 108 M-l and 1.14 × l08 M-1, respectively, and were 4-fold higher than its divalent scFv [sc(Fv)2; 2.75 × 107 M-1. At 6 h postadministration, the percentage of injected dose accumulated/g of LS-174T colon carcinoma xenografts was 21.3 ± 1.3, 9.8 ± 1.3, and 17.3 ± 1.1 for radioiodinated [sc(Fv)2]2, sc(Fv)2, and IgG, respectively. Pharmacokinetic analysis of blood clearance studies showed the elimination half-life for [sc(Fv)2]2, sc(Fv)2, and IgG as 170, 80, and 330 min, respectively. The gain in avidity resulting from multivalency along with an improved biological half-life makes the tetravalent construct an important reagent for cancer therapy and diagnosis in MAb-based radiopharmaceuticals.

AB - Failure of radiolabeled monoclonal antibodies (MAbs) in the treatment of solid tumors, for the most part, is a result of undesirable pharmacokinetics that lead to significant radiation exposure of normal tissues and an inadequate delivery of radiation doses to tumors. Using genetic engineering, antitumor MAbs can be optimized for desirable clinical applications. In the present study, we report the generation of a tetravalent single-chain Fv {[sc(Fv)2]2} of the murine MAb CC49 that recognizes the tumor-associated glycoprotein, TAG-72. [Sc(Fv)2]2 was expressed as a secreted soluble protein in Pichia pastoris under the regulation of alcohol oxidase 1 promoter. The in vitro binding properties of the tetravalent construct were analyzed by solid-phase RIA and surface plasmon resonance studies using BIAcore. The binding affinity constant (KA) for the [sc(Fv)2]2 and CC49 IgG were similar, i.e., 1.02 × 108 M-l and 1.14 × l08 M-1, respectively, and were 4-fold higher than its divalent scFv [sc(Fv)2; 2.75 × 107 M-1. At 6 h postadministration, the percentage of injected dose accumulated/g of LS-174T colon carcinoma xenografts was 21.3 ± 1.3, 9.8 ± 1.3, and 17.3 ± 1.1 for radioiodinated [sc(Fv)2]2, sc(Fv)2, and IgG, respectively. Pharmacokinetic analysis of blood clearance studies showed the elimination half-life for [sc(Fv)2]2, sc(Fv)2, and IgG as 170, 80, and 330 min, respectively. The gain in avidity resulting from multivalency along with an improved biological half-life makes the tetravalent construct an important reagent for cancer therapy and diagnosis in MAb-based radiopharmaceuticals.

UR - http://www.scopus.com/inward/record.url?scp=0034671309&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034671309&partnerID=8YFLogxK

M3 - Article

VL - 60

SP - 6964

EP - 6971

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 24

ER -